Home > > > > > Report Detail

Vulvovaginal Candidiasis - Pipeline Insight, 2022

Publisher Name :
Date: 31-Mar-2022
No. of pages: 40
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Vulvovaginal Candidiasis," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal Candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Vulvovaginal Candidiasis Understanding

Vulvovaginal Candidiasis: Overview

Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Other names for this infection are "vaginal candidiasis," "vulvovaginal candidiasis," or "candidal vaginitis." The symptoms of vaginal candidiasis include: Vaginal itching or soreness, pain during sexual intercourse, pain or discomfort when urinating, abnormal vaginal discharge. Although most vaginal candidiasis is mild, some women can develop severe infections involving redness, swelling, and cracks in the wall of the vagina. Vaginal candidiasis is common, though more research is needed to understand how many women are affected. Women who are more likely to get vaginal candidiasis include those who: Are pregnant, use hormonal contraceptives (for example, birth control pills), have diabetes, have a weakened immune system (for example, due to HIV infection or medicines that weaken the immune system, such as steroids and chemotherapy). Healthcare providers usually diagnose vaginal candidiasis by taking a small sample of vaginal discharge to be examined under a microscope in the medical office or sent to a laboratory for a fungal culture. However, a positive fungal culture does not always mean that Candida is causing symptoms because some women can have Candida in the vagina without having any symptoms. Vaginal candidiasis is usually treated with antifungal medicine. For most infections, the treatment is an antifungal medicine applied inside the vagina or a single dose of fluconazole taken by mouth. Other treatments may be needed for infections that are more severe, that don't get better, or that keep coming back after getting better.

"Vulvovaginal Candidiasis- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal Candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal Candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal Candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal Candidiasis.

Vulvovaginal Candidiasis Emerging Drugs Chapters

This segment of the Vulvovaginal Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vulvovaginal Candidiasis Emerging Drugs

- Oteseconazole : Mycovia Pharmaceuticals

Oteseconazole (VT-1161) is a novel, investigational oral therapy for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC.Mycovia Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC).

- MAT2203: Matinas BioPharma

MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn't simply stop fungus from growing, but kills it entirely. The drug is currently in phase 2 stage of development for the treatment of Vulvovaginal Candidiasis.

- Benzydamine/econazole : Angelini Pharmaceuticals

Angelini Pharmaceuticals is developing an antimycotic vaginal pessary combination comprising benzydamine hydrochloride 6mg and econazole nitrate 150mg in the Treatment of uncomplicated vulvovaginal Candidiasis. To assess the microbiological and clinical efficacy, the safety and acceptability of the benzydamine HCl 6 mg and econazole nitrate 150 mg vaginal pessary, in comparison to Pevaryl® 150 mg vaginal pessary, in the treatment of uncomplicated VVC.Currently, the drug is in Phase 3 stage of development for the treatment of Vulvovaginal Candidiasis.

- Miconazole/Domiphen Bromide: Hyloris Pharmaceuticals

MCZ-DB is a locally applied vaginal cream, and based on promising results from preclinical studies, it is believed that it could have significant potential in recurring VVC infections, an underserved condition for which there are no locally administered topical therapies currently available. Miconazole-Domiphen Bromide is being developed in Phase 2 stage of development, in partnership with Purna Female Health (PFH).

Further product details are provided in the report……..

Vulvovaginal Candidiasis: Therapeutic Assessment

This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Vulvovaginal Candidiasis

There are approx. 7+ key companies which are developing the therapies for Vulvovaginal Candidiasis. The companies which have their Vulvovaginal Candidiasis drug candidates in the most advanced stage, i.e. Pre-Registration include, Mycovia Pharmaceuticals.

- Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Vulvovaginal Candidiasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intra-articular

- Intraocular

- Intrathecal

- Intravenous

- Ophthalmic

- Oral

- Parenteral

- Subcutaneous

- Topical

- Transdermal

- Molecule Type

Products have been categorized under various Molecule types such as

- Oligonucleotide

- Peptide

- Small molecule

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vulvovaginal Candidiasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal Candidiasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal Candidiasis drugs.

Vulvovaginal Candidiasis Report Insights

- Vulvovaginal Candidiasis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Vulvovaginal Candidiasis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Vulvovaginal Candidiasis drugs?

- How many Vulvovaginal Candidiasis drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vulvovaginal Candidiasis?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vulvovaginal Candidiasis therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Vulvovaginal Candidiasis and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Mycovia Pharmaceuticals

- Matinas BioPharma

- NovaDigm Therapeutics

- Toltec Pharmaceuticals

- LTN Pharm

- ProFem

- Ferrer

- Mariposa Health

Key Products

- Oteseconazole

- MAT2203

- NDV 3

- Benzydamine/econazole

- Miconazole/Domiphen Bromide

- TOL 463

Vulvovaginal Candidiasis - Pipeline Insight, 2022

Table of Contents

Introduction
Executive Summary
Vulvovaginal Candidiasis: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Vulvovaginal Candidiasis- DelveInsight's Analytical Perspective
Late Stage Products (Pre Registration)
* Comparative Analysis
Oteseconazole : Mycovia Pharmaceuticals
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
End Stage Products (Phase III)
* Comparative Analysis
Benzydamine/econazole : Angelini Pharmaceuticals
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..

Mid Stage Products (Phase II)
* Comparative Analysis
MAT2203: Matinas BioPharma
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
* Comparative Analysis
Drug Name:Company Name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
* Comparative Analysis
Vulvovaginal Candidiasis Key Companies
Vulvovaginal Candidiasis Key Products
Vulvovaginal Candidiasis- Unmet Needs
Vulvovaginal Candidiasis- Market Drivers and Barriers
Vulvovaginal Candidiasis- Future Perspectives and Conclusion
Vulvovaginal Candidiasis Analyst Views
Vulvovaginal Candidiasis Key Companies
Appendix

List of Tables

Table 1 Total Products for Vulvovaginal Candidiasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Vulvovaginal Candidiasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......
  • Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......
  • Global Contraceptives Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141
    According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......
  • Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108
    According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......
  • Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......
  • Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139
    Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......
  • Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122
    Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......
  • Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......
  • Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs